ORPEA Publishes the Summary of the External Assessment Report on the Use of Public Funds and Business Relations With Third Parties
ORPEA has released the final conclusions of audits by Grant Thornton and Alvarez & Marsal in response to allegations regarding the misuse of public funds and business relations with officials. The audits found no evidence of significant misconduct, although issues related to unreported discounts and questionable practices were identified. The company has since implemented remedial measures and is pursuing legal actions against implicated individuals. CEO Philippe Charrier emphasized transparency and commitment to restructuring, with new CEO Laurent Guillot set to lead these efforts from July 1.
- No evidence found of significant misconduct regarding public fund usage.
- Introduction of emergency measures to correct internal processes.
- Commitment to transparency and stakeholder engagement.
- Identified issues with unreported discounts affecting financial integrity.
- High payments to third-party intermediaries raised concerns.
- Ongoing legal and disciplinary actions against implicated management.
The final conclusions of these firms on the subjects relating to the care of nursing home residents and to employment law will be made available to the public, in the same format and under the same conditions, as soon as possible following their transmission to the Company by the end of June at the latest.
“The publication of the conclusions of the external evaluation mission is in line with the full transparency approach adopted by the Board of Directors in response to the allegations made against the Group. Although the report demonstrates that some of these allegations cannot be substantiated, it also confirms failures and misconduct for which, once again, we would like to offer our most sincere apologies to all of our stakeholders. Since the departure of the former Chief Executive Officer on
The use of public funds
With regard to allegations relating to the improper use of public funds intended for the Group’s nursing homes in
-
found no evidence to support the following allegations:
- maneuvering in the management of inspections by the authorities;
- falsifying the production of supporting documentation intended for the authorities.
-
observed:
- non-eligible or excessive amounts declared to the authorities due to the lack of reliability of the workforce declaration processes;
- a lack of reliability in the process for matching purchase orders, delivery notes and purchase invoices, which didn’t allow the systematic detection of any fraud;
- the granting of year-end discounts by certain important suppliers of products financed by public allowances not disclosed to the authorities as intended. These year-end discounts have allowed to fund Group activities or investments that were not directly care or dependency-related;
- a practice, which has been discontinued since 2017, of maximizing the consumption of the allowance for medical devices granted by the authorities to nursing homes. This was done through the invoicing by one supplier of services whose reality could not be verified and from which the Group benefited via the year-end discounts mechanism;
- the existence of surpluses in the allocations received from the authorities, the accounting treatment of which may have contributed to the Group's results; the existence of under-utilization of allocations received from the public authorities. The surpluses thus generated may have contributed to the Group's results.
Prior to the submission of the findings of these reports,
The results of all of these investigations were brought to the attention of the statutory auditors during their review of the financial statements for the 2021 financial year, as has this Press Release. The financial impact of the conclusions of these investigations has, to the best of the Group's knowledge, been taken into account in the financial statements approved by the Board of Directors.
Business relations with third parties
However,
These remunerations were identified by the Group during its recent internal investigations and some of them are already included, among other transactions, in the complaint filed by
The legal and disciplinary actions taken by
The complaint against X filed by
- capital partnerships, in particular during external growth transactions outside of
- other economic transactions, in
In support of those facts,
In this regard, investigations carried out by
Disciplinary procedures are under way against all managers identified to date as having been involved in the events addressed in the complaint. Redundancies and dismissals have already been carried out.
Meanwhile, the terms of office of these individuals, when they held any, have been (or are currently in the process of being) terminated.
It is reminded that the work of
About
Founded in 1989,
View source version on businesswire.com: https://www.businesswire.com/news/home/20220608006000/en/
Investor Relations Director
Investor Relations Director
b.lesieur@orpea.net
Investor Relations
NewCap
Dusan Oresansky
Tel.: +33 (0)1 44 71 94 94
orpea@newcap.eu
Media Relations
Image 7
Tel.: +33 (0)6 78 37 27 60
clebarbier@image7.fr
Tél.: +33(0)6 89 87 61 24
Caroline.simon@image7.fr
Source:
FAQ
What conclusions did ORPEA's audits reveal regarding public fund use on June 8, 2022?
When will ORPEA publish the final conclusions of the audits?
Who is taking over as CEO of ORPEA on July 1, 2022?
What actions is ORPEA taking in response to the audit findings?